Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Agalsidase Beta,Paracetamol,Diphenhydramine,Dexamethasone,Montelukast Sodium,Loratadine,Cetirizine,Fexofenadine Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
August 31, 2023
Lead Product(s) : Agalsidase Beta,Paracetamol,Diphenhydramine,Dexamethasone,Montelukast Sodium,Loratadine,Cetirizine,Fexofenadine Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab,Fexofenadine Hydrochloride,Loratadine
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
March 02, 2022
Lead Product(s) : Dupilumab,Fexofenadine Hydrochloride,Loratadine
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Loratadine,Inapplicable
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides Receives USFDA Approval for Loratadine OTC Softgel Capsules
Details : USFDA approved generic version Loratadine Softgel Capsules is an antihistamine that treats symptoms such as itching, runny nose, watery eyes, and sneezing from "hay fever" and other allergies.
Product Name : Claritin Liqui-Gels-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 16, 2020
Lead Product(s) : Loratadine,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acyclovir,Methylprednisolone,Alemtuzumab,Paracetamol,Loratadine,Cetirizine,Dexchloropheniramine Maleate
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 22, 2015
Lead Product(s) : Acyclovir,Methylprednisolone,Alemtuzumab,Paracetamol,Loratadine,Cetirizine,Dexchloropheniramine Maleate
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Triamcinolone Acetonide,Loratadine
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2010
Lead Product(s) : Triamcinolone Acetonide,Loratadine
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BMS-986446,Paracetamol,Loratadine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 02, 2025
Lead Product(s) : BMS-986446,Paracetamol,Loratadine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Loratadine,Inapplicable
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Marksans Pharma Gains After Receiving Final Nod for Loratadine Tablets from USFDA
Details : Clartin-Generic (loratadine) is been approved by USFDA. It is indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for OTC.
Product Name : Clartin-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 22, 2024
Lead Product(s) : Loratadine,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibuprofen,Loratadine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2024
Lead Product(s) : Ibuprofen,Loratadine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Histaglobulin,Loratadine
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
February 09, 2024
Lead Product(s) : Human Histaglobulin,Loratadine
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olopatadine Hydrochloride,Loratadine,Hypromellosum
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2022
Lead Product(s) : Olopatadine Hydrochloride,Loratadine,Hypromellosum
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable